Abstract | BACKGROUND: MATERIALS AND METHODS: Serum levels of cathepsin B in 60 healthy controls, 80 patients with benign prostatic hypertrophy (BPH) and 120 patients with prostate cancer were measured by a sandwich enzyme immunoassay. Cathepsin B-D was calculated by dividing the serum levels of cathepsin B by the prostate volume, which was measured using transrectal ultrasonography. We subsequently analyzed the association between these two factors and several clinicopathological factors. RESULTS: CONCLUSION: These findings indicate that the elevation of serum cathepsin B and cathepsin B-D could be used as novel predictors of disease extension, but not survival, in patients with prostate cancer.
|
Authors | Hideaki Miyake, Isao Hara, Hiroshi Eto |
Journal | Anticancer research
(Anticancer Res)
2004 Jul-Aug
Vol. 24
Issue 4
Pg. 2573-7
ISSN: 0250-7005 [Print] Greece |
PMID | 15330217
(Publication Type: Journal Article)
|
Chemical References |
- Biomarkers, Tumor
- Cathepsin B
|
Topics |
- Aged
- Aged, 80 and over
- Biomarkers, Tumor
(blood)
- Case-Control Studies
- Cathepsin B
(blood)
- Disease Progression
- Humans
- Male
- Middle Aged
- Prostatic Hyperplasia
(enzymology, pathology)
- Prostatic Neoplasms
(enzymology, pathology)
|